Can FDG-PET be used to predict growth of stage I lung cancer?

Clinical Radiology

Volumn 63, Issue 8, 2008, Pages 856-863

  Tann, M ^a   Sandrasegaran, K ^a   Winer Muram, H T ^b   Jennings, S G ^a   Welling, M E ^a   Fletcher, J W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Richard L Roudebush VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; GROWTH RATE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 46749157885     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2008.01.012     Document Type: Article

References (37)

1. Mountain C.F. Staging classification of lung cancer. A critical evaluation. Clin Chest Med 23 (2002) 103-121
2. Ginsberg R., Cox J., Green M., et al. Staging classification committee. Lung Cancer 17 Suppl. 1 (1997) S11-S13
3. Ambrogi M.C., Lucchi M., Dini P., et al. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg 30 (2006) 177-183
4. Hiraki T., Sakurai J., Tsuda T., et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumours: evaluation based on a preliminary review of 342 tumours. Cancer 107 (2006) 2873-2880
5. Matsuoka T., and Okuma T. CT-guided radiofrequency ablation for lung cancer. Int J Clin Oncol 12 (2007) 71-78
6. Usuda K., Saito Y., Sagawa M., et al. Tumour doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74 (1994) 2239-2244
7. Winer-Muram H.T., Jennings S.G., Tarver R.D., et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 223 (2002) 798-805
8. Jerusalem G., Hustinx R., Beguin Y., et al. PET scan imaging in oncology. Eur J Cancer 39 (2003) 1525-1534
9. Maisey M.N. Overview of clinical PET. Br J Radiol 75 (2002) S1-S5
10. Bomanji J.B., Costa D.C., and Ell P.J. Clinical role of positron emission tomography in oncology. Lancet Oncol 2 (2001) 157-164
11. Minn H., Joensuu H., Ahonen A., et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 61 (1988) 1776-1781
12. Okada J., Yoshikawa K., Itami M., et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33 (1992) 325-329
13. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17 (1999) 3201-3206
14. Ahuja V., Coleman R.E., Herndon J., et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83 (1998) 918-924
15. Duhaylongsod F.G., Lowe V.J., Patz Jr. E.F., et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60 (1995) 1348-1352
16. Yankelevitz D.F., Reeves A.P., Kostis W.J., et al. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology 217 (2000) 251-256
17. Revel M.P., Merlin A., Peyrard S., et al. Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol 187 (2006) 135-142
18. Arai T., Kuroishi T., Saito Y., et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 24 (1994) 199-204
19. Lindell R.M., Hartman T.E., Swensen S.J., et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 242 (2007) 555-562
20. Patz Jr. E.F., Lowe V.J., Hoffman J.M., et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188 (1993) 487-490
21. Gupta N.C., Frank A.R., Dewan N.A., et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 184 (1992) 441-444
22. Knight S.B., Delbeke D., Stewart J.R., et al. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 109 (1996) 982-988
23. Valk P.E., Pounds T.R., Hopkins D.M., et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 60 (1995) 1573-1581
24. Wahl R.L., Quint L.E., Greenough R.L., et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191 (1994) 371-377
25. Scott W.J., Schwabe J.L., Gupta N.C., et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 58 (1994) 698-703
26. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
27. Harpole Jr. D.H., Herndon J.E., Wolfe W.G., et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55 (1995) 51-56
28. Apolinario R.M., van d V., de Jong J.S., et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15 (1997) 2456-2466
29. Harpole Jr. D.H., Richards W.G., Herndon J.E., et al. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61 (1996) 1470-1476
30. Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest 65 (1974) 3-8
31. Henschke C.I., McCauley D.I., Yankelevitz D.F., et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 354 (1999) 99-105
32. Lowe V.J., Hoffman J.M., Delong D.M., et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35 (1994) 1771-1776
33. Keyes Jr. J.W. SUV: standard uptake or silly useless value?. J Nucl Med 36 (1995) 1836-1839
34. Hamberg L.M., Hunter G.J., Alpert N.M., et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med 35 (1994) 1308-1312
35. Bogot N.R., Kazerooni E.A., Kelly A.M., et al. Interobserver and intraobserver variability in the assessment of pulmonary nodule size on CT using film and computer display methods. Acad Radiol 12 (2005) 948-956
36. Zhao B., Schwartz L.H., Moskowitz C.S., et al. Pulmonary metastases: effect of CT section thickness on measurement-initial experience. Radiology 234 (2005) 934-939
37. Petrou M., Quint L.E., Nan B., et al. Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology. AJR Am J Roentgenol 188 (2007) 306-312